DMS: Sale of the DMS Wellness division – 12/01/2022 at 6:00 p.m.


Wishing to focus on its two main activities, namely medtech, through its DMS Imaging division, and biotech through Hybrigenics and its subsidiaries which make up the DMS Biotech division,

Diagnostic Medical Systems Group (Euronext Paris – FR0012202497 – DGM)

announces the sale of its DMS Wellness division to CES Management SA, majority shareholder of Swiss company BEBO Health, specializing in the distribution of innovative and exclusive products dedicated to health, sport and well-being (Euronext Access – CH1148983609 – MLBBO)

The DMS Wellness pole brought together the activities of DMS Group dedicated to the health and well-being sector, aimed at specialists in physiotherapy, beauty, aesthetics, sport and health. DMS Wellness notably marketed the Celliss solution, high-end body care equipment dedicated to slimming and anti-cellulite treatments, the distribution of which will now be handled by BEBO Health.

At 1

er

half-year 2021, this division represented a turnover of 0.1 M € (on a total turnover of the Group of 18.3 M €) and an EBITDA loss of -0.2 M € (on a Total Group EBITDA of + € 0.9m).

In view of the obvious synergies with the portfolio of products and equipment of BEBO Health and its business model, this sale constitutes the best alternative to allow DMS Wellness to reach critical size and to continue its development.

This transaction, carried out in cash and in securities, is effective as of this day.


About DMS Group

DMS Group

is made up of companies with high innovation potential. First focused on the medical imaging industry, it is now expanding into new horizons. By investing in the future and betting on research, DMS Group hopes to provide the solutions of tomorrow.

  • Specialized in high technology in the service of medical diagnostics,

    DMS Imaging

    is today positioned as the French leader in the development, design and manufacture of imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.

  • DMS Biotech

    , made up of Hybrigenics and its subsidiaries, supports the group’s development strategy in the field of biotechnologies, and particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells. Hybrigenics is listed on the Euronext Growth market in Paris (ISIN: FR0004153930 – mnemo: ALHYG).

DMS Group is present on all continents through a network of more than 140 national distributors, subsidiaries and joint ventures.

DMS Group is listed on the Euronext market in Paris (ISIN: FR0012202497 – mnemo: DGM).

More information on

www.dms.com

.


Contacts:

DMS Group


Jean-Paul ANSEL

Chairman and CEO

04 67 50 49 00

FINANCE NEWS


Mathieu OMNES

Investor Relations

01 53 67 36 92

FINANCE NEWS


Fatou KINE N’DIAYE

Press relations

01 53 67 36 34


This publication has the service “? Actusnews SECURITY MASTER”.


– SECURITY MASTER Key:

yWqbYZpukmqaymttlZaabmJkbWZjm5HKaWfGmmlqa5eabm2WyGlhmpvGZnBjnGZt

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Issuer operations (acquisitions, disposals, etc.)


Full and original press release in PDF format:

https://www.actusnews.com/news/72717-dms_cp_cession-wellness-12012022_en.pdf

© Copyright Actusnews Wire

Receive free company updates by email by subscribing to www.actusnews.com



Source link -86